Compare Edwards Lifesciences Corporation Common Stock (EW) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Koninklijke Philips NV — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.24 (market cap $48.56B), while Koninklijke Philips NV trades at $24.32 (market cap $23.52B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 2.1× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays a 4.17% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | PHG | |
|---|---|---|
Market Cap | $48.56B | $23.52B |
Volume | 6,520,488 | 1,635,069 |
Sector | Health | Health |
52-Week High | $95.18 | $32.91 |
52-Week Low | $72.65 | $23.81 |
Enterprise Value | $45.01B | $29.87B |
Typical Hold Time | — | 84 Days |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
